These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 33298918)
1. Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors. Wang C; Zhang L; Ke L; Ding W; Jiang S; Li D; Narita Y; Hou I; Liang J; Li S; Xiao H; Gottwein E; Kaye KM; Teng M; Zhao B Nat Commun; 2020 Dec; 11(1):6318. PubMed ID: 33298918 [TBL] [Abstract][Full Text] [Related]
2. Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma. Manzano M; Günther T; Ju H; Nicholas J; Bartom ET; Grundhoff A; Gottwein E mBio; 2020 Aug; 11(4):. PubMed ID: 32843547 [TBL] [Abstract][Full Text] [Related]
3. TAF Family Proteins and MEF2C Are Essential for Epstein-Barr Virus Super-Enhancer Activity. Wang C; Jiang S; Zhang L; Li D; Liang J; Narita Y; Hou I; Zhong Q; Gewurz BE; Teng M; Zhao B J Virol; 2019 Aug; 93(16):. PubMed ID: 31167905 [TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939 [TBL] [Abstract][Full Text] [Related]
5. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. Patil A; Manzano M; Gottwein E Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751 [TBL] [Abstract][Full Text] [Related]
11. The hyper-activation of transcriptional enhancers in breast cancer. Li QL; Wang DY; Ju LG; Yao J; Gao C; Lei PJ; Li LY; Zhao XL; Wu M Clin Epigenetics; 2019 Mar; 11(1):48. PubMed ID: 30867030 [TBL] [Abstract][Full Text] [Related]
12. Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. Ryan RJ; Drier Y; Whitton H; Cotton MJ; Kaur J; Issner R; Gillespie S; Epstein CB; Nardi V; Sohani AR; Hochberg EP; Bernstein BE Cancer Discov; 2015 Oct; 5(10):1058-71. PubMed ID: 26229090 [TBL] [Abstract][Full Text] [Related]
13. Enhancer identification in mouse embryonic stem cells using integrative modeling of chromatin and genomic features. Chen CY; Morris Q; Mitchell JA BMC Genomics; 2012 Apr; 13():152. PubMed ID: 22537144 [TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma. Lam BQ; Dai L; Li L; Qiao J; Lin Z; Qin Z Oncotarget; 2017 Mar; 8(11):18373-18380. PubMed ID: 28407694 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus. Zhang YJ; Patel D; Nan Y; Fan S Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187 [TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2. Portal D; Zhou H; Zhao B; Kharchenko PV; Lowry E; Wong L; Quackenbush J; Holloway D; Jiang S; Lu Y; Kieff E Proc Natl Acad Sci U S A; 2013 Nov; 110(46):18537-42. PubMed ID: 24167291 [TBL] [Abstract][Full Text] [Related]
17. Transcriptional Dysregulation of MYC Reveals Common Enhancer-Docking Mechanism. Schuijers J; Manteiga JC; Weintraub AS; Day DS; Zamudio AV; Hnisz D; Lee TI; Young RA Cell Rep; 2018 Apr; 23(2):349-360. PubMed ID: 29641996 [TBL] [Abstract][Full Text] [Related]
18. SOX2 represses c-MYC transcription by altering the co-activator landscape of the c-MYC super-enhancer and promoter regions. Ormsbee Golden BD; Gonzalez DV; Yochum GS; Coulter DW; Rizzino A J Biol Chem; 2024 Sep; 300(9):107642. PubMed ID: 39122009 [TBL] [Abstract][Full Text] [Related]
19. 3D genomic analysis reveals novel enhancer-hijacking caused by complex structural alterations that drive oncogene overexpression. Mortenson KL; Dawes C; Wilson ER; Patchen NE; Johnson HE; Gertz J; Bailey SD; Liu Y; Varley KE; Zhang X Nat Commun; 2024 Jul; 15(1):6130. PubMed ID: 39033128 [TBL] [Abstract][Full Text] [Related]
20. A model of active transcription hubs that unifies the roles of active promoters and enhancers. Zhu I; Song W; Ovcharenko I; Landsman D Nucleic Acids Res; 2021 May; 49(8):4493-4505. PubMed ID: 33872375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]